Bristol-Myers joins the IDO rush with its own in-house combo program for Opdivo
WASHINGTON, DC — While Bristol-Myers Squibb joined the rush to partner with Incyte on its leading IDO1 drug epacadostat, it’s also been zeroing in on its own IDO immunotherapy. And investigators turned up at AACR this year with an early look at the results.
Bottom line: Bristol-Myers is going for it.
“It seems our IDO has the potential to be one of the most potent in the class,” Bristol-Myers oncology development chief Faoud Namouni tells me. But it’s still early days.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
